Cover Page
Cover Page - shares | 3 Months Ended | |
Mar. 31, 2022 | Apr. 29, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2022 | |
Document Transition Report | false | |
Entity File Number | 1-37774 | |
Entity Registrant Name | AdvanSix Inc. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 81-2525089 | |
Entity Address, Address Line One | 300 Kimball Drive | |
Entity Address, Address Line Two | Suite 101 | |
Entity Address, City or Town | Parsippany | |
Entity Address, State or Province | NJ | |
Entity Address, Postal Zip Code | 07054 | |
City Area Code | 973 | |
Local Phone Number | 526-1800 | |
Title of 12(b) Security | Common Stock, par value $0.01 per share | |
Trading Symbol | ASIX | |
Security Exchange Name | NYSE | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 28,103,293 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q1 | |
Entity Central Index Key | 0001673985 | |
Amendment Flag | false |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Income Statement [Abstract] | ||
Sales | $ 479,073 | $ 376,383 |
Costs, expenses and other: | ||
Costs of goods sold | 375,646 | 317,899 |
Selling, general and administrative expenses | 21,210 | 19,308 |
Interest expense, net | 563 | 1,544 |
Other non-operating (income) expense, net | (603) | 230 |
Total costs, expenses and other | 396,816 | 338,981 |
Income before taxes | 82,257 | 37,402 |
Income tax expense | 19,184 | 9,271 |
Net income | $ 63,073 | $ 28,131 |
Earnings per common share | ||
Basic (in dollars per share) | $ 2.24 | $ 1 |
Diluted (in dollars per share) | $ 2.15 | $ 0.98 |
Weighted average common shares outstanding | ||
Basic (in shares) | 28,199,871 | 28,093,764 |
Diluted (in shares) | 29,371,051 | 28,741,066 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Statement of Comprehensive Income [Abstract] | ||
Net income | $ 63,073 | $ 28,131 |
Foreign exchange translation adjustment | 57 | (70) |
Cash-flow hedges | 512 | 483 |
Other comprehensive income (loss), net of tax | 569 | 413 |
Comprehensive income | $ 63,642 | $ 28,544 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 19,306 | $ 15,100 |
Accounts and other receivables – net | 223,541 | 179,087 |
Inventories – net | 163,396 | 149,570 |
Other current assets | 6,220 | 6,097 |
Total current assets | 412,463 | 349,854 |
Property, plant and equipment – net | 782,783 | 767,964 |
Operating lease right-of-use assets | 132,567 | 136,207 |
Goodwill | 57,863 | 17,592 |
Intangible assets | 48,948 | 17,980 |
Other assets | 22,497 | 22,402 |
Total assets | 1,457,121 | 1,311,999 |
Current liabilities: | ||
Accounts payable | 200,524 | 211,511 |
Accrued liabilities | 40,203 | 49,712 |
Income taxes payable | 27,656 | 9,723 |
Operating lease liabilities – short-term | 36,435 | 36,127 |
Deferred income and customer advances | 2,434 | 2,749 |
Total current liabilities | 307,252 | 309,822 |
Deferred income taxes | 145,206 | 133,330 |
Operating lease liabilities – long-term | 96,471 | 100,580 |
Line of credit – long-term | 220,000 | 135,000 |
Postretirement benefit obligations | 19,451 | 18,243 |
Other liabilities | 10,350 | 13,834 |
Total liabilities | 798,730 | 710,809 |
COMMITMENTS AND CONTINGENCIES (Note 9) | ||
STOCKHOLDERS' EQUITY | ||
Common stock, par value $0.01; 200,000,000 shares authorized; 31,900,305 shares issued and 28,103,293 outstanding at March 31, 2022; 31,755,430 shares issued and 28,139,954 outstanding at December 31, 2021 | 319 | 318 |
Preferred stock, par value $0.01; 50,000,000 shares authorized and 0 shares issued and outstanding at March 31, 2022 and December 31, 2021 | 0 | 0 |
Treasury stock at par (3,797,012 shares at March 31, 2022; 3,615,476 shares at December 31, 2021) | (38) | (36) |
Additional paid-in capital | 193,321 | 195,931 |
Retained earnings | 470,759 | 411,516 |
Accumulated other comprehensive loss | (5,970) | (6,539) |
Total stockholders' equity | 658,391 | 601,190 |
Total liabilities and stockholders' equity | $ 1,457,121 | $ 1,311,999 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares | Mar. 31, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Common stock par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, shares issued (in shares) | 31,900,305 | 31,755,430 |
Common stock, shares outstanding (in shares) | 28,103,293 | 28,139,954 |
Preferred stock par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized (in shares) | 50,000,000 | 50,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Treasury stock (in shares) | 3,797,012 | 3,615,476 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Cash flows from operating activities: | ||
Net income | $ 63,073 | $ 28,131 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Depreciation and amortization | 16,692 | 16,104 |
Loss on disposal of assets | 359 | 84 |
Deferred income taxes | (519) | 2,237 |
Stock-based compensation | 3,374 | 2,363 |
Accretion of deferred financing fees | 155 | 141 |
Changes in assets and liabilities, net of business acquisitions: | ||
Accounts and other receivables | (28,402) | (13,170) |
Inventories | (1,889) | 38,986 |
Accounts payable | (8,029) | (13,781) |
Income taxes payable | 17,933 | 0 |
Accrued liabilities | (11,718) | 912 |
Deferred income and customer advances | (315) | (6,803) |
Other assets and liabilities | (1,552) | 1,886 |
Net cash provided by operating activities | 49,162 | 57,090 |
Cash flows from investing activities: | ||
Expenditures for property, plant and equipment | (21,019) | (14,177) |
Acquisition of business | (98,589) | (9,523) |
Other investing activities | (296) | (231) |
Net cash used for investing activities | (119,904) | (23,931) |
Cash flows from financing activities: | ||
Borrowings from line of credit | 148,500 | 54,000 |
Payments of line of credit | (63,500) | (83,000) |
Principal payments of finance leases | (237) | (199) |
Dividend payments | (3,517) | 0 |
Purchase of treasury stock | (7,012) | (443) |
Issuance of common stock | 714 | 1 |
Net cash provided by (used for) financing activities | 74,948 | (29,641) |
Net change in cash and cash equivalents | 4,206 | 3,518 |
Cash and cash equivalents at beginning of period | 15,100 | 10,606 |
Cash and cash equivalents at the end of period | 19,306 | 14,124 |
Supplemental non-cash investing activities: | ||
Capital expenditures included in accounts payable | 7,335 | 2,965 |
Supplemental cash activities: | ||
Cash paid for interest | 408 | 1,518 |
Cash paid for income taxes | $ 22 | $ 35 |
CONDENSED CONSOLIDATED STATEM_4
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-In Capital | Retained Earnings | Treasury Stock | Accumulated Other Comprehensive Income (Loss) |
Beginning balance (in shares) at Dec. 31, 2020 | 31,627,139 | |||||
Beginning balance at Dec. 31, 2020 | $ 444,123 | $ 316 | $ 184,732 | $ 275,243 | $ (36) | $ (16,132) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net income | 28,131 | 28,131 | ||||
Comprehensive income | ||||||
Foreign exchange translation adjustment | (70) | (70) | ||||
Cash-flow hedges | 483 | 483 | ||||
Pension obligation adjustments | 0 | |||||
Other comprehensive income (loss), net of tax | 413 | 413 | ||||
Issuance of common stock (in shares) | 33,200 | |||||
Issuance of common stock | 1 | $ 1 | ||||
Purchase of treasury stock | (443) | (443) | ||||
Stock-based compensation | 2,363 | 2,363 | ||||
Ending balance (in shares) at Mar. 31, 2021 | 31,660,339 | |||||
Ending balance at Mar. 31, 2021 | $ 474,588 | $ 317 | 186,652 | 303,374 | (36) | (15,719) |
Beginning balance (in shares) at Dec. 31, 2021 | 28,139,954 | 31,755,430 | ||||
Beginning balance at Dec. 31, 2021 | $ 601,190 | $ 318 | 195,931 | 411,516 | (36) | (6,539) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net income | 63,073 | 63,073 | ||||
Comprehensive income | ||||||
Foreign exchange translation adjustment | 57 | 57 | ||||
Cash-flow hedges | 512 | 512 | ||||
Pension obligation adjustments | 0 | |||||
Other comprehensive income (loss), net of tax | 569 | 569 | ||||
Issuance of common stock (in shares) | 144,875 | |||||
Issuance of common stock | 714 | $ 1 | 713 | |||
Purchase of treasury stock | (7,012) | (7,010) | (2) | |||
Stock-based compensation | 3,374 | 3,374 | ||||
Dividends | $ (3,517) | 313 | (3,830) | |||
Ending balance (in shares) at Mar. 31, 2022 | 28,103,293 | 31,900,305 | ||||
Ending balance at Mar. 31, 2022 | $ 658,391 | $ 319 | $ 193,321 | $ 470,759 | $ (38) | $ (5,970) |
CONDENSED CONSOLIDATED STATEM_5
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - shares | 3 Months Ended | 37 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2022 | |
Statement of Stockholders' Equity [Abstract] | |||
Stock repurchased during period (in shares) | 181,536 | 15,371 | 3,797,012 |
Organization, Operations and Ba
Organization, Operations and Basis of Presentation | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Organization, Operations and Basis of Presentation | Organization, Operations and Basis of Presentation Description of Business AdvanSix Inc. ("AdvanSix," the "Company," "we" or "our") plays a critical role in global supply chains, innovating and delivering essential products for our customers in a wide variety of end markets and applications that touch people’s lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. Our reliable and sustainable supply of quality products emerges from the integrated value chain of our five U.S.-based manufacturing facilities. AdvanSix strives to deliver best-in-class customer experiences and differentiated products in the industries of nylon solutions, chemical intermediates and plant nutrients, guided by our core values of Safety, Integrity, Accountability and Respect. COVID-19 Since early 2020, the novel coronavirus (COVID-19) has continued to spread, with confirmed cases worldwide, and with certain jurisdictions experiencing resurgences, including as a result of variant strains. The pandemic and related containment measures, such as travel bans and restrictions, shelter in place orders and business shutdowns, have had a substantial impact on businesses around the world and on global, regional and national economies, including disruptions to supply chains, volatility in demand, production and sales across most industries, volatility within global financial markets, inflationary pressures in commodity pricing and an increasingly dynamic workforce environment. The continuously evolving nature of this pandemic and the pace and shape of a full recovery may continue to have an impact on the United States and global economies. The Company’s Condensed Consolidated Financial Statements reflect estimates and assumptions made by management that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and reported amounts of revenue and expenses during the reporting periods presented. The Company continues to consider the impact of COVID-19 on the estimates and assumptions used for the financial statements. As previously disclosed, the Company experienced a material impact on its second quarter 2020 results of operations associated with lower demand, particularly in nylon, caprolactam and phenol, and a decrease in overall sales volume related to global markets and the economic impact of COVID-19. Starting in the second half of 2020, and through the first quarter of 2022, demand improved to pre-COVID-19 levels with states, regions and countries in various phases of re-opening and continued administration of vaccines for COVID-19. The Company will continue to monitor developments and execute our operational and safety mitigation plans as previously disclosed. As the situation surrounding COVID-19 remains fluid and unpredictable, the Company cannot reasonably estimate with any degree of certainty the future impact COVID-19 may have on the Company’s results of operations, financial position, and liquidity. Basis of Presentation The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company's financial position as of March 31, 2022, and its results of operations for the three months ended March 31, 2022 and 2021 and cash flows for the three months ended March 31, 2022 and 2021. The year-end Condensed Consolidated Balance Sheet data were derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the full fiscal year. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the "2021 Form 10-K"). All intercompany transactions have been eliminated. Certain prior period amounts have been reclassified for consistency with the current period presentation. It is our practice to establish actual quarterly closing dates using a predetermined fiscal calendar, which requires our businesses to close their books on a Saturday in order to minimize the potentially disruptive effects of quarterly closing on our business processes. Historically, the effects of this practice were generally not significant to reported results for any quarter and only existed within a reporting year. In the event that differences in actual closing dates are material to year-over-year comparisons of quarterly or year-to-date results, we will provide the appropriate disclosures. Our actual closing dates for the three months ended March 31, 2022 and 2021 wer e April 2, 2022 and April 3, 2021, respe ctively. Liabilities to creditors to whom we have issued checks that remained outstanding at March 31, 2022 and December 31, 2021 aggregated to $2.2 million and $4.5 million, respectively, and were included in Cash and cash equivalents and Accounts payable in the Condensed Consolidated Balance Sheets. On May 4, 2018, the Company announced that its Board of Directors (the “Board”) authorized a share repurchase program of up to $75 million of the Company’s common stock. On February 22, 2019, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company's common stock, which was in addition to the remaining capacity available under the May 2018 share repurchase program. Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The share repurchase program has no expiration date and may be modified, suspended or discontinued at any time. The par value of the shares repurchased is applied to Treasury stock and the excess of the purchase price over par value is applied to Additional paid-in capital. During the first quarter of 2022, the Company repurchased 181,536 shares of common stock, including 57,968 shares to cover tax withholding obligations in connection with the vesting of awards, for an aggregate of $7.0 million at a weighted average market price of $38.61 per share. As of March 31, 2022, the Company had repurchased 3,797,012 shares of common stock, including 583,682 shares withheld to cover tax withholding obligations in connection with the vesting of awards, for an aggregate of $109.4 million at a weighted average market price of $28.81 per share. As of March 31, 2022, $54.8 million remained available for share repurchases under the current authorization. During the period April 1, 2022 through April 29, 2022, no additional shares were repurchased under the currently authorized repurchase program. |
Recent Accounting Pronouncement
Recent Accounting Pronouncements | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Recent Accounting Pronouncements – The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). Any ASUs not currently adopted were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations. |
Revenues
Revenues | 3 Months Ended |
Mar. 31, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Revenues | Revenues Revenue Recognition We serve approximately 400 customers annually in approximately 50 countries and across a wide variety of industries. For the three months ended March 31, 2022 and 2021, the Company's ten largest customers accounted for approximately 37% and 38% of total sales, respectively. We typically sell to customers under master service agreements, with primarily one-year terms, or by purchase orders. We have historically experienced low customer turnover and have long-standing customer relationships, which span decades. Our largest customer is Shaw Industries Group, Inc. (“Shaw”), a significant consumer of caprolactam and Nylon 6 resin, to whom we sell under a long-term agreement. For the three months ended March 31, 2022 and 2021, the Company's sales to Shaw were 9% and 12% of our total sales, respectively. The Company's revenue by product line, and related approximate percentage of total sales, for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended 2022 2021 Nylon $ 118,609 25% $ 83,789 22% Caprolactam 70,005 15% 80,403 21% Chemical Intermediates 135,690 28% 141,360 38% Ammonium Sulfate 154,769 32% 70,831 19% $ 479,073 100% $ 376,383 100% The Company's revenues by geographic area, and related approximate percentage of total sales, for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended 2022 2021 United States $ 403,018 84 % $ 300,672 80 % International 76,055 16 % 75,711 20 % Total $ 479,073 100 % $ 376,383 100 % Deferred Income and Customer Advances The Company defers revenues when cash payments are received in advance of our performance. Below is a roll-forward of Deferred income and customer advances for the three months ended March 31, 2022: Opening balance January 1, 2022 $ 2,749 Additional cash advances 640 Less amounts recognized in revenues (955) Ending balance March 31, 2022 $ 2,434 The Company expects to recognize as revenue the March 31, 2022 ending balance of Deferred income and customer advances within one year or less. |
Earnings Per Share
Earnings Per Share | 3 Months Ended |
Mar. 31, 2022 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Earnings Per Share The computation of basic and diluted earnings per share ("EPS") is based on Net income divided by the basic weighted average number of common shares and diluted weighted average number of common shares, respectively. The details of the basic and diluted EPS calculations for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended 2022 2021 Basic Net income $ 63,073 $ 28,131 Weighted average common shares outstanding 28,199,871 28,093,764 EPS – Basic $ 2.24 $ 1.00 Diluted Dilutive effect of equity awards and other stock-based holdings 1,171,180 647,302 Weighted average common shares outstanding 29,371,051 28,741,066 EPS – Diluted $ 2.15 $ 0.98 Diluted EPS is computed based upon the weighted average number of common shares outstanding for the period plus the dilutive effect of common stock equivalents using the treasury stock method and the average market price of our common stock for the period. The diluted EPS calculations exclude the effect of stock options when the options’ assumed proceeds exceed the average market price of the common shares during the period. The anti-dilutive common stock equivalents outstanding at the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended 2022 2021 Options and stock equivalents 120,316 861,376 Dividend activity for the three months ended March 31, 2022 and 2021 was as follows: Three Months Ended 2022 2021 Cash dividends declared per share $ 0.125 $ — Aggregate dividends paid to shareholders $ 3,517 $ — |
Accounts and Other Receivables
Accounts and Other Receivables – Net | 3 Months Ended |
Mar. 31, 2022 | |
Receivables [Abstract] | |
Accounts and Other Receivables – Net | Accounts and Other Receivables – Net March 31, December 31, Accounts receivables $ 220,010 $ 175,584 Other 4,870 4,998 Total accounts and other receivables 224,880 180,582 Less – allowance for doubtful accounts (1,339) (1,495) Total accounts and other receivables – net $ 223,541 $ 179,087 |
Inventories
Inventories | 3 Months Ended |
Mar. 31, 2022 | |
Inventory Disclosure [Abstract] | |
Inventories | Inventories March 31, December 31, Raw materials $ 90,299 $ 56,961 Work in progress 52,578 43,526 Finished goods 57,374 27,961 Spares and other 27,679 27,150 227,930 155,598 Reduction to LIFO cost basis (64,534) (6,028) Total inventories $ 163,396 $ 149,570 Substantially all of the Company’s inventories at March 31, 2022 and December 31, 2021 are valued at the lower of cost or market using the last-in, first-out (“LIFO”) method. However, approximately 9% was valued at average cost using the first-in, first-out (“FIFO”) method at March 31, 2022. The excess of replacement cost over the carrying value of total inventories subject to LIFO was $72.5 million and $29.4 million at March 31, 2022 and December 31, 2021, respectively. |
Leases
Leases | 3 Months Ended |
Mar. 31, 2022 | |
Leases [Abstract] | |
Leases | LeasesWe determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use assets ("ROU"), Operating lease liabilities – short-term, and Operating lease liabilities – long-term in our Condensed Consolidated Balance Sheets. Finance leases are included in Property, plant and equipment – net, Accounts payable, and Other liabilities in our Condensed Consolidated Balance Sheets. The components of lease expense were as follows: Three Months Ended 2022 2021 Finance lease cost: Amortization of right-of-use asset $ 236 $ 183 Interest on lease liabilities 14 8 Total finance lease cost 250 191 Operating lease cost 10,339 11,571 Short-term lease cost 1,353 1,913 Total lease cost $ 11,942 $ 13,675 As of March 31, 2022, we have additional finance leases that have not yet commenced for approximately $0.5 million. These leases will commence during 2022 with lease terms of up to 5 years. |
Leases | LeasesWe determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use assets ("ROU"), Operating lease liabilities – short-term, and Operating lease liabilities – long-term in our Condensed Consolidated Balance Sheets. Finance leases are included in Property, plant and equipment – net, Accounts payable, and Other liabilities in our Condensed Consolidated Balance Sheets. The components of lease expense were as follows: Three Months Ended 2022 2021 Finance lease cost: Amortization of right-of-use asset $ 236 $ 183 Interest on lease liabilities 14 8 Total finance lease cost 250 191 Operating lease cost 10,339 11,571 Short-term lease cost 1,353 1,913 Total lease cost $ 11,942 $ 13,675 As of March 31, 2022, we have additional finance leases that have not yet commenced for approximately $0.5 million. These leases will commence during 2022 with lease terms of up to 5 years. |
Goodwill and Intangible Assets
Goodwill and Intangible Assets | 3 Months Ended |
Mar. 31, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Intangible Assets | Goodwill and Intangible Assets Intangible assets with finite lives acquired through a business combination are recorded at fair value, less accumulated amortization. Customer relationships and trade-names are amortized on a straight-line basis over their expected useful lives of 15 to 20 years and 5 years, respectively. Goodwill The change in the carrying amount of goodwill was as follows: Total Balance at December 31, 2021 $ 17,592 Acquisition of U.S. Amines 40,271 Balance at March 31, 2022 $ 57,863 Finite-Lived Intangible Assets Intangible assets subject to amortization were as follows: March 31, 2022 December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Book Value Gross Carrying Amount Accumulated Amortization Net Book Value Customer relationships $ 34,220 $ (423) $ 33,797 $ 3,920 $ (240) $ 3,680 Licenses 18,451 (4,382) 14,069 18,451 (4,151) 14,300 Trade names 1,100 (18) 1,082 — — — Total $ 53,771 $ (4,823) $ 48,948 $ 22,371 $ (4,391) $ 17,980 For the three months ended March 31, 2022 and March 31, 2021, the Company recorded amortization expense on intangible assets of $0.4 million and $0.3 million, respectively. |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies The Company is subject to a number of lawsuits, investigations and disputes, some of which may involve substantial amounts claimed, arising out of the conduct of the Company or other third-parties in the normal and ordinary course of business. A liability is recognized for any contingency that is probable of occurrence and reasonably estimable. The Company continually assesses the likelihood of adverse judgments or outcomes in these matters, as well as potential ranges of possible losses, based |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The provision for income taxes was $19.2 million and $9.3 million for the three months ended March 31, 2022 and 2021, respectively, resulting in an effective tax rate of 23.3% and 24.8%, respectively. The Company’s provision for income taxes in interim periods is computed by applying an estimated annual effective tax rate against Income (Loss) before taxes for the period in addition to recording any tax effects of discrete items for the quarter. The Company’s estimated annual effective tax rate applied against the three months ended March 31, 2022 and 2021 differed from the U.S. federal statutory rate, due primarily to state taxes and executive compensation deduction limitations which generally increase the tax rate, partially offset by tax credits and the foreign-derived intangible income deduction which generally decrease the tax rate. In February 2022, the Company acquired the stock of U.S. Amines, Ltd. Under purchase accounting rules, a net deferred tax liability of approximately $12.2 million was recorded in the quarter related to the adjustment of the acquired assets and liabilities to fair value. See Note 13 "Acquisitions" for further details. |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements Financial and non-financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. In July 2019, the Company entered into an interest rate swap transaction related to its credit agreement. The fair value of the interest rate swap at March 31, 2022 was a loss of approximately $0.04 million and is considered a Level 2 liability. The pension plan assets are invested in collective investment trust funds. These investments are measured at fair value using the net asset value per share as a practical expedient. Investments valued using the net asset value method (NAV) (or its equivalent) practical expedient are excluded from the fair value hierarchy disclosure. The Company’s Condensed Consolidated Balance Sheets also include Cash and cash equivalents, Accounts receivable and Accounts payable all of which are recorded at amounts which approximate fair value. |
Derivative and Hedging Instrume
Derivative and Hedging Instruments | 3 Months Ended |
Mar. 31, 2022 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative and Hedging Instruments | Derivative and Hedging Instruments The specific credit and market, commodity price and interest rate risks to which the Company is exposed in connection with its ongoing business operations are described below. This discussion includes an explanation of the hedging instrument and interest rate swap agreement, used to manage the Company’s interest rate risk associated with a fixed and floating-rate borrowing. For cash flow hedges, the entire change in the fair value of the hedging instrument included in the assessment of hedge effectiveness is recorded in Other comprehensive income. Those amounts are reclassified to earnings in the same income statement line item that is used to present the earnings effect of the hedged item when the hedged item affects earnings. Credit and Market Risk – Financial instruments, including derivatives, expose the Company to counterparty credit risk for non-performance and to market risk related to changes in commodity prices, interest rates and foreign currency exchange rates. The Company manages its exposure to counterparty credit risk through specific minimum credit standards, diversification of counterparties, and procedures to monitor concentrations of credit risk. The Company’s counterparties in derivative transactions are substantial investment and commercial banks with significant experience using such derivative instruments. The Company monitors the impact of market risk on the fair value and cash flows of its derivative and other financial instruments considering reasonably possible changes in commodity prices, interest rates and foreign currency exchange rates and restricts the use of derivative financial instruments to hedging activities. The Company continually monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. The terms and conditions of credit sales are designed to mitigate or eliminate concentrations of credit risk with any single customer. The Company did not have any customers with significant concentrations of trade accounts receivable – net at March 31, 2022 or December 31, 2021. Allowance for doubtful accounts is calculated based upon the Company's estimate of expected credit losses over the life of exposure based upon both historical information as well as future expected losses. Commodity Price Risk Management – The Company's exposure to market risk for commodity prices can result in changes in the cost of production. We primarily mitigate our exposure to commodity price risk by using long-term, formula-based price contracts with our suppliers and formula-based price agreements with customers. Our customer agreements provide for price adjustments based on relevant market indices and raw material prices and generally do not include take-or-pay terms. We may also enter into forward commodity contracts with third-parties designated as hedges of anticipated purchases of several commodities. Forward commodity contracts are marked-to-market, with the resulting gains and losses recognized in earnings, in the same category as the items being hedged, when the hedged transaction is recognized. At March 31, 2022 and 2021, we had no financial contracts related to forward commodity agreements. Interest Rate Risk Management – The Company has entered into one interest rate swap agreement for a total notional amount of $50 million to exchange floating for fixed rate interest payments for our LIBOR-based borrowings. The interest rate swap had a fair value of zero at inception and was effective July 31, 2019 with a maturity date of February 21, 2023. In accordance with ASC 815, the Company designated the interest rate swap as a cash flow hedge of floating-rate borrowings. The interest rate swap converts the Company’s interest rate payments on the first $50 million of variable-rate, 1-month LIBOR-based debt to a fixed interest rate. The interest rate swap involves the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the interest rate swap without an exchange of the underlying principal amount. Liability Derivatives March 31, 2022 December 31, 2021 Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments under ASC 815: Interest Rate Contracts Accrued liabilities and Other liabilities $ (44) Accrued liabilities and Other liabilities $ (708) Total Derivatives $ (44) $ (708) The following table summarizes adjustments related to cash flow hedge included in Cash-flow hedges, in the Condensed Consolidated Statements of Comprehensive Income: March 31, Loss on derivative instruments included in Accumulated other comprehensive loss at December 31, 2021 $ (708) Fair value adjustment 664 Loss on derivative instruments included in Accumulated other comprehensive loss at March 31, 2022 $ (44) At March 31, 2022, the Company expects to reclassify approximately $0.04 million of net losses on derivative instruments from Accumulated other comprehensive income ("AOCI") to earnings during the next 12 months due to the payment of variable interest associated with the floating rate debt with the remainder recognized in future periods through the expiration date. The following table summarizes the reclassification of net losses on derivative instruments from AOCI into earnings: Amount of Loss Recognized in Earnings Three Months Ended 2022 2021 Derivatives: Interest Rate Contracts $ 12 $ 557 Total Derivatives $ 12 $ 557 |
Acquisitions
Acquisitions | 3 Months Ended |
Mar. 31, 2022 | |
Business Combination and Asset Acquisition [Abstract] | |
Acquisitions | Acquisitions In February 2022, the Company acquired U.S. Amines, Ltd. ("U.S. Amines"), a leading North American producer of alkyl and specialty amines serving high-value end markets such as agrochemicals and pharmaceuticals for an estimated purchase price of approximately $98 million, net of cash acquired. U.S. Amines employs approximately 50 people in the United States at manufacturing facilities in Bucks, AL and Portsmouth, VA. In accordance with ASC 805, this transaction has been accounted for as a business combination. The Company used its best estimates and assumptions for items including, but not limited to, corporate name recognition, strong, long-lasting customer relationships and potential revenue growth from existing customers to assign fair value to the tangible and identifiable intangible assets acquired and liabilities assumed at the acquisition date based on the information that was available as of the acquisition date. The transaction resulted in the Company acquiring tangible assets and finite-lived intangible assets, comprised of customer relationships (approximately $30 million) and trademarks (approximately $1 million) which reflect the value of the benefit derived from incremental revenue and related cash flows as a direct result of the customer relationships and name brand. These intangible assets are being amortized on a straight-line basis over their estimated useful lives of 20 years and 5 years, respectively. The residual amount of the purchase price in excess of the value of the tangible and definite-lived intangible assets was allocated to goodwill. Factors considered when identifying goodwill included, but are not limited to, a complementary business model and formula pricing mechanisms with a business that is adjacent to our ammonium sulfate adjuvant and solvent businesses, the enhancement of the Company’s value chain through internal supply of products and raw materials, a new unique platform in the agrochemicals space as well as a number of opportunities to support further penetration into high-value applications. The U.S. Amines acquisition was not significant to our Condensed Consolidated Financial Statements, therefore, pro forma and post-acquisition results of operations have not been presented. The preliminary measurements of fair value set forth herein are subject to change and such changes could be material. The Company expects to finalize the valuation as soon as practicable, but no later than one year from the acquisition date. In January 2021, the Company acquired certain assets associated with ammonium sulfate packaging, warehousing and logistics services in Virginia from Commonwealth Industrial Services, Inc. ("CIS") for approximately $9.5 million. This acquisition enables the Company to expand its product offerings by directly supplying packaged ammonium sulfate to customers, primarily in North and South America. It diversifies and optimizes our product offerings to include spray-grade adjuvant to support crop protection and products for industrial use. The Company also expects the addition of packaging and warehousing capabilities to bolster logistics and operational efficiency across its Richmond, Virginia area plants. The transaction resulted in the Company acquiring tangible assets and a finite-lived intangible asset, comprised of customer relationships which reflects the value of the benefit derived from incremental revenue and related cash flows as a direct result of the customer relationships. This intangible asset is being amortized on a straight-line basis over its estimated useful life of 15 years. The residual amount of the purchase price in excess of the value of the tangible and definite-lived intangible assets was allocated to goodwill The following table summarizes the allocation of the purchase price consideration as of the acquisition date for the transactions noted above: U.S. Amines (February 2022 - Preliminary) CIS Cash $ 22,887 $ — Accounts receivable 15,117 858 Inventories 11,937 712 Other current assets 1,876 — Property, plant and equipment 13,600 1,875 Intangible assets 31,400 3,920 Accounts payable (1,487) (429) Accrued liabilities (2,760) — Deferred income taxes (12,243) — Net tangible and intangible assets 80,327 6,936 Goodwill 40,271 2,587 Total purchase price $ 120,598 $ 9,523 Total purchase price $ 120,598 $ 9,523 Less: Cash acquired (22,887) — Total purchase price, net of cash received 97,711 9,523 Estimated working capital adjustment due from seller 878 — Net cash paid $ 98,589 $ 9,523 Goodwill deductible for tax purposes $ — $ 2,587 |
Subsequent Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2022 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent EventsAs announced on May 6, 2022, the Board declared a quarterly cash dividend of $0.125 per share on the Company's common stock, payable on May 31, 2022 to stockholders of record as of the close of business on May 17, 2022. |
Recent Accounting Pronounceme_2
Recent Accounting Pronouncements (Policies) | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation | The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company's financial position as of March 31, 2022, and its results of operations for the three months ended March 31, 2022 and 2021 and cash flows for the three months ended March 31, 2022 and 2021. The year-end Condensed Consolidated Balance Sheet data were derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the full fiscal year. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the "2021 Form 10-K"). All intercompany transactions have been eliminated. Certain prior period amounts have been reclassified for consistency with the current period presentation. It is our practice to establish actual quarterly closing dates using a predetermined fiscal calendar, which requires our businesses to close their books on a Saturday in order to minimize the potentially disruptive effects of quarterly closing on our business processes. Historically, the effects of this practice were generally not significant to reported results for any quarter and only existed within a reporting year. In the event that differences in actual closing dates are material to year-over-year comparisons of quarterly or year-to-date results, we will provide the appropriate disclosures. Our actual closing dates for the three months ended March 31, 2022 and 2021 wer e April 2, 2022 and April 3, 2021, respe ctively. |
New Accounting Pronouncements | Recent Accounting Pronouncements – The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). Any ASUs not currently adopted were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations. |
Revenues (Tables)
Revenues (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Disaggregation of Revenue | The Company's revenue by product line, and related approximate percentage of total sales, for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended 2022 2021 Nylon $ 118,609 25% $ 83,789 22% Caprolactam 70,005 15% 80,403 21% Chemical Intermediates 135,690 28% 141,360 38% Ammonium Sulfate 154,769 32% 70,831 19% $ 479,073 100% $ 376,383 100% The Company's revenues by geographic area, and related approximate percentage of total sales, for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended 2022 2021 United States $ 403,018 84 % $ 300,672 80 % International 76,055 16 % 75,711 20 % Total $ 479,073 100 % $ 376,383 100 % |
Summary of Deferred Income and Customer Advances | Below is a roll-forward of Deferred income and customer advances for the three months ended March 31, 2022: Opening balance January 1, 2022 $ 2,749 Additional cash advances 640 Less amounts recognized in revenues (955) Ending balance March 31, 2022 $ 2,434 |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings Per Share | The details of the basic and diluted EPS calculations for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended 2022 2021 Basic Net income $ 63,073 $ 28,131 Weighted average common shares outstanding 28,199,871 28,093,764 EPS – Basic $ 2.24 $ 1.00 Diluted Dilutive effect of equity awards and other stock-based holdings 1,171,180 647,302 Weighted average common shares outstanding 29,371,051 28,741,066 EPS – Diluted $ 2.15 $ 0.98 |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The anti-dilutive common stock equivalents outstanding at the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended 2022 2021 Options and stock equivalents 120,316 861,376 |
Schedule of Dividends Declared | Dividend activity for the three months ended March 31, 2022 and 2021 was as follows: Three Months Ended 2022 2021 Cash dividends declared per share $ 0.125 $ — Aggregate dividends paid to shareholders $ 3,517 $ — |
Accounts and Other Receivable_2
Accounts and Other Receivables - Net (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Receivables [Abstract] | |
Schedule of Accounts and Other Receivables Net | March 31, December 31, Accounts receivables $ 220,010 $ 175,584 Other 4,870 4,998 Total accounts and other receivables 224,880 180,582 Less – allowance for doubtful accounts (1,339) (1,495) Total accounts and other receivables – net $ 223,541 $ 179,087 |
Inventories (Tables)
Inventories (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory, Current | March 31, December 31, Raw materials $ 90,299 $ 56,961 Work in progress 52,578 43,526 Finished goods 57,374 27,961 Spares and other 27,679 27,150 227,930 155,598 Reduction to LIFO cost basis (64,534) (6,028) Total inventories $ 163,396 $ 149,570 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Leases [Abstract] | |
Components of Lease Expense | The components of lease expense were as follows: Three Months Ended 2022 2021 Finance lease cost: Amortization of right-of-use asset $ 236 $ 183 Interest on lease liabilities 14 8 Total finance lease cost 250 191 Operating lease cost 10,339 11,571 Short-term lease cost 1,353 1,913 Total lease cost $ 11,942 $ 13,675 |
Goodwill and Intangible Assets
Goodwill and Intangible Assets (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Changes in Carrying Amount of Goodwill | The change in the carrying amount of goodwill was as follows: Total Balance at December 31, 2021 $ 17,592 Acquisition of U.S. Amines 40,271 Balance at March 31, 2022 $ 57,863 |
Schedule of Finite-Lived Intangible Assets | Intangible assets subject to amortization were as follows: March 31, 2022 December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Book Value Gross Carrying Amount Accumulated Amortization Net Book Value Customer relationships $ 34,220 $ (423) $ 33,797 $ 3,920 $ (240) $ 3,680 Licenses 18,451 (4,382) 14,069 18,451 (4,151) 14,300 Trade names 1,100 (18) 1,082 — — — Total $ 53,771 $ (4,823) $ 48,948 $ 22,371 $ (4,391) $ 17,980 |
Derivative and Hedging Instru_2
Derivative and Hedging Instruments (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value | Liability Derivatives March 31, 2022 December 31, 2021 Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments under ASC 815: Interest Rate Contracts Accrued liabilities and Other liabilities $ (44) Accrued liabilities and Other liabilities $ (708) Total Derivatives $ (44) $ (708) |
Derivative Instruments, Gain (Loss) | The following table summarizes adjustments related to cash flow hedge included in Cash-flow hedges, in the Condensed Consolidated Statements of Comprehensive Income: March 31, Loss on derivative instruments included in Accumulated other comprehensive loss at December 31, 2021 $ (708) Fair value adjustment 664 Loss on derivative instruments included in Accumulated other comprehensive loss at March 31, 2022 $ (44) |
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) | The following table summarizes the reclassification of net losses on derivative instruments from AOCI into earnings: Amount of Loss Recognized in Earnings Three Months Ended 2022 2021 Derivatives: Interest Rate Contracts $ 12 $ 557 Total Derivatives $ 12 $ 557 |
Acquisitions (Tables)
Acquisitions (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Business Combination and Asset Acquisition [Abstract] | |
Schedule of Business Acquisitions | The following table summarizes the allocation of the purchase price consideration as of the acquisition date for the transactions noted above: U.S. Amines (February 2022 - Preliminary) CIS Cash $ 22,887 $ — Accounts receivable 15,117 858 Inventories 11,937 712 Other current assets 1,876 — Property, plant and equipment 13,600 1,875 Intangible assets 31,400 3,920 Accounts payable (1,487) (429) Accrued liabilities (2,760) — Deferred income taxes (12,243) — Net tangible and intangible assets 80,327 6,936 Goodwill 40,271 2,587 Total purchase price $ 120,598 $ 9,523 Total purchase price $ 120,598 $ 9,523 Less: Cash acquired (22,887) — Total purchase price, net of cash received 97,711 9,523 Estimated working capital adjustment due from seller 878 — Net cash paid $ 98,589 $ 9,523 Goodwill deductible for tax purposes $ — $ 2,587 |
Organization, Operations and _2
Organization, Operations and Basis of Presentation (Details) | 1 Months Ended | 3 Months Ended | 37 Months Ended | ||||
Apr. 29, 2022shares | Mar. 31, 2022USD ($)manufacuringSite$ / sharesshares | Mar. 31, 2021shares | Mar. 31, 2022USD ($)manufacuringSite$ / sharesshares | Dec. 31, 2021USD ($) | Feb. 22, 2019USD ($) | May 04, 2018USD ($) | |
Accounting Policies [Abstract] | |||||||
Number of manufacturing sites | manufacuringSite | 5 | 5 | |||||
Liabilities to creditors, payments issued but outstanding | $ 2,200,000 | $ 2,200,000 | $ 4,500,000 | ||||
Share repurchase program, maximum amount of shares authorized to be repurchased | $ 75,000,000 | $ 75,000,000 | |||||
Shares of common stock covering the tax withholding obligations (in shares) | shares | 57,968 | 583,682 | |||||
Stock repurchased during period, value | $ 7,000,000 | $ 109,400,000 | |||||
Treasury stock acquired, weighted average cost per share (in dollars per share) | $ / shares | $ 38.61 | $ 28.81 | |||||
Stock repurchase program, remaining authorized repurchase amount | $ 54,800,000 | $ 54,800,000 | |||||
Subsequent Event [Line Items] | |||||||
Stock repurchased during period (in shares) | shares | 181,536 | 15,371 | 3,797,012 | ||||
Subsequent Event | |||||||
Subsequent Event [Line Items] | |||||||
Stock repurchased during period (in shares) | shares | 0 |
Revenues - Narrative (Details)
Revenues - Narrative (Details) | 3 Months Ended | |
Mar. 31, 2022customercountry | Mar. 31, 2021 | |
Concentration Risk [Line Items] | ||
Number of customers | customer | 400 | |
Number of countries in which customers are located (more than) | country | 50 | |
Length of contract terms | We typically sell to customers under master service agreements, with primarily one-year terms, or by purchase orders. | |
10 Largest Customers | Customer Concentration Risk | Revenue from Contract with Customer | ||
Concentration Risk [Line Items] | ||
Concentration risk percentage | 37.00% | 38.00% |
Shaw Industries Group Inc | Customer Concentration Risk | Revenue from Contract with Customer | ||
Concentration Risk [Line Items] | ||
Concentration risk percentage | 9.00% | 12.00% |
Revenues - Disaggregation of Re
Revenues - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Disaggregation of Revenue [Line Items] | ||
Sales | $ 479,073 | $ 376,383 |
Percentage of sales | 100.00% | 100.00% |
United States | ||
Disaggregation of Revenue [Line Items] | ||
Sales | $ 403,018 | $ 300,672 |
Percentage of sales | 84.00% | 80.00% |
International | ||
Disaggregation of Revenue [Line Items] | ||
Sales | $ 76,055 | $ 75,711 |
Percentage of sales | 16.00% | 20.00% |
Nylon | ||
Disaggregation of Revenue [Line Items] | ||
Sales | $ 118,609 | $ 83,789 |
Percentage of sales | 25.00% | 22.00% |
Caprolactam | ||
Disaggregation of Revenue [Line Items] | ||
Sales | $ 70,005 | $ 80,403 |
Percentage of sales | 15.00% | 21.00% |
Chemical Intermediates | ||
Disaggregation of Revenue [Line Items] | ||
Sales | $ 135,690 | $ 141,360 |
Percentage of sales | 28.00% | 38.00% |
Ammonium Sulfate | ||
Disaggregation of Revenue [Line Items] | ||
Sales | $ 154,769 | $ 70,831 |
Percentage of sales | 32.00% | 19.00% |
Revenues - Summary of Deferred
Revenues - Summary of Deferred Revenue and Customer Advances (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2022USD ($) | |
Change in Contract with Customer, Liability [Roll Forward] | |
Opening balance | $ 2,749 |
Additional cash advances | 640 |
Less amounts recognized in revenues | (955) |
Ending balance | $ 2,434 |
Earnings Per Share - Schedule o
Earnings Per Share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Basic | ||
Net income | $ 63,073 | $ 28,131 |
Weighted average common shares outstanding (in shares) | 28,199,871 | 28,093,764 |
EPS – Basic (in dollars per share) | $ 2.24 | $ 1 |
Diluted | ||
Dilutive effect of equity awards and other stock-based holdings (in shares) | 1,171,180 | 647,302 |
Weighted average common shares outstanding (in shares) | 29,371,051 | 28,741,066 |
EPS – Diluted (in dollars per share) | $ 2.15 | $ 0.98 |
Earnings Per Share - Antidiluti
Earnings Per Share - Antidilutive Common Stock Equivalents (Details) - shares | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Earnings Per Share [Abstract] | ||
Options and stock equivalents (in shares) | 120,316 | 861,376 |
Earnings Per Share - Dividend A
Earnings Per Share - Dividend Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Earnings Per Share [Abstract] | ||
Cash dividends declared per share (in dollars per share) | $ 0.125 | $ 0 |
Aggregate dividends paid to shareholders | $ 3,517 | $ 0 |
Accounts and Other Receivable_3
Accounts and Other Receivables - Net (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Receivables [Abstract] | ||
Accounts receivables | $ 220,010 | $ 175,584 |
Other | 4,870 | 4,998 |
Total accounts and other receivables | 224,880 | 180,582 |
Less – allowance for doubtful accounts | (1,339) | (1,495) |
Total accounts and other receivables – net | $ 223,541 | $ 179,087 |
Inventories (Details)
Inventories (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 90,299 | $ 56,961 |
Work in progress | 52,578 | 43,526 |
Finished goods | 57,374 | 27,961 |
Spares and other | 27,679 | 27,150 |
Inventory gross | 227,930 | 155,598 |
Reduction to LIFO cost basis | (64,534) | (6,028) |
Total inventories | $ 163,396 | 149,570 |
Percentage of FIFO inventory | 9.00% | |
Excess of replacement or current costs over stated LIFO value | $ 72,500 | $ 29,400 |
Leases - Components of Lease Ex
Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Finance Lease Cost | ||
Amortization of right-of-use asset | $ 236 | $ 183 |
Interest on lease liabilities | 14 | 8 |
Total finance lease cost | 250 | 191 |
Operating lease cost | 10,339 | 11,571 |
Short-term lease cost | 1,353 | 1,913 |
Total lease cost | $ 11,942 | $ 13,675 |
Leases - Narrative (Details)
Leases - Narrative (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2022USD ($) | |
Leases [Abstract] | |
Operating lease not yet commenced | $ 0.5 |
Operating lease, commence lease period | 5 years |
Goodwill and Intangible Asset_2
Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | |
Feb. 28, 2022 | Mar. 31, 2022 | Mar. 31, 2021 | |
Finite-Lived Intangible Assets [Line Items] | |||
Amortization of intangible assets | $ 0.4 | $ 0.3 | |
Customer Relationships | U.S. Amines, Ltd. | |||
Finite-Lived Intangible Assets [Line Items] | |||
Useful life | 20 years | ||
Customer Relationships | U.S. Amines, Ltd. | Minimum | |||
Finite-Lived Intangible Assets [Line Items] | |||
Useful life | 15 years | ||
Customer Relationships | U.S. Amines, Ltd. | Maximum | |||
Finite-Lived Intangible Assets [Line Items] | |||
Useful life | 20 years | ||
Trade names | U.S. Amines, Ltd. | |||
Finite-Lived Intangible Assets [Line Items] | |||
Useful life | 5 years |
Goodwill and Intangible Asset_3
Goodwill and Intangible Assets - Schedule of Changes in Carrying Amount of Goodwill (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2022USD ($) | |
Goodwill [Roll Forward] | |
Beginning balance | $ 17,592 |
Acquisitions | 40,271 |
Ending balance | $ 57,863 |
Goodwill and Intangible Asset_4
Goodwill and Intangible Assets - Schedule of Gross Carrying Value and Accumulated Amortization for Each Major Class of Intangible Asset (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Finite-Lived Intangible Assets [Line Items] | ||
Amortized intangible assets - Gross Carrying Amount | $ 53,771 | $ 22,371 |
Amortized intangible assets - Accumulated Amortization | (4,823) | (4,391) |
Amortized intangible assets - Net | 48,948 | 17,980 |
Customer Relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
Amortized intangible assets - Gross Carrying Amount | 34,220 | 3,920 |
Amortized intangible assets - Accumulated Amortization | (423) | (240) |
Amortized intangible assets - Net | 33,797 | 3,680 |
Licenses | ||
Finite-Lived Intangible Assets [Line Items] | ||
Amortized intangible assets - Gross Carrying Amount | 18,451 | 18,451 |
Amortized intangible assets - Accumulated Amortization | (4,382) | (4,151) |
Amortized intangible assets - Net | 14,069 | 14,300 |
Trade names | ||
Finite-Lived Intangible Assets [Line Items] | ||
Amortized intangible assets - Gross Carrying Amount | 1,100 | 0 |
Amortized intangible assets - Accumulated Amortization | (18) | 0 |
Amortized intangible assets - Net | $ 1,082 | $ 0 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) | 3 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |||
Income tax expense | $ 19,184,000 | $ 9,271,000 | |
Effective income tax rate | 23.30% | 24.80% | |
Business Acquisition [Line Items] | |||
Deferred income taxes | $ 145,206,000 | $ 133,330,000 | |
U.S. Amines, Ltd. | |||
Business Acquisition [Line Items] | |||
Deferred income taxes | $ 12,200,000 |
Fair Value Measurements (Detail
Fair Value Measurements (Details) | 3 Months Ended | ||
Mar. 31, 2022USD ($)derivative_instrument | Jul. 31, 2019USD ($) | Nov. 30, 2018USD ($) | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Impairment for goodwill | $ 0 | ||
Interest Rate Swap | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Number of instruments held | derivative_instrument | 1 | ||
Derivative liability, fair value | $ 0 | $ 0 | |
Fair Value, Inputs, Level 2 | Interest Rate Swap | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Derivative liability, fair value | $ 40,000 |
Derivative and Hedging Instru_3
Derivative and Hedging Instruments - Narrative (Details) | 3 Months Ended | |
Mar. 31, 2022USD ($)derivative_instrument | Dec. 31, 2021derivative_instrument | |
Derivative Instruments, Gain (Loss) [Line Items] | ||
Derivative loss reclassification from AOCI to income | $ | $ 40,000 | |
Forward Commodity Agreements | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Number of instruments held | derivative_instrument | 0 | 0 |
Interest Rate Swap | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Number of instruments held | derivative_instrument | 1 | |
Derivative, notional amount | $ | $ 50,000,000 |
Derivative and Hedging Instru_4
Derivative and Hedging Instruments - Balance Sheet Classification (Details) - Designated as Hedging Instrument - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Derivative [Line Items] | ||
Derivative liability, fair value | $ (44) | $ (708) |
Interest Rate Contracts | ||
Derivative [Line Items] | ||
Derivative liability, fair value | $ (44) | $ (708) |
Derivative and Hedging Instru_5
Derivative and Hedging Instruments - Adjustments Related to Cash Flow Hedges on the Comprehensive Income Statement (Details) - Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent $ in Thousands | 3 Months Ended |
Mar. 31, 2022USD ($) | |
AOCI Attributable To Parent, Before Tax [Roll Forward] | |
Loss on derivative instruments included in Accumulated other comprehensive loss at December 31, 2021 | $ (708) |
Fair value adjustment | 664 |
Loss on derivative instruments included in Accumulated other comprehensive loss at March 31, 2022 | $ (44) |
Derivative and Hedging Instru_6
Derivative and Hedging Instruments - Amount of Loss Recognized in Earning (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Derivative Instruments, Gain (Loss) [Line Items] | ||
Total Derivatives | $ 63,073 | $ 28,131 |
Amount of Loss Recognized in Earnings | Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Total Derivatives | 12 | 557 |
Amount of Loss Recognized in Earnings | Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest | Interest Rate Contracts | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Total Derivatives | $ 12 | $ 557 |
Acquisitions - Business Combina
Acquisitions - Business Combination (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | |||
Feb. 28, 2022USD ($)employer | Jan. 31, 2021USD ($) | Mar. 31, 2022USD ($) | Mar. 31, 2021USD ($) | Dec. 31, 2021USD ($) | |
Business Acquisition [Line Items] | |||||
Acquisition of business | $ 98,589 | $ 9,523 | |||
Purchase Price | |||||
Goodwill | 57,863 | $ 17,592 | |||
Acquisition of business | $ 98,589 | $ 9,523 | |||
U.S. Amines, Ltd. | |||||
Business Acquisition [Line Items] | |||||
Acquisition of business | $ 97,711 | ||||
Number of employees | employer | 50 | ||||
Purchase Price | |||||
Cash | $ 22,887 | ||||
Accounts receivable | 15,117 | ||||
Inventories | 11,937 | ||||
Other current assets | 1,876 | ||||
Property, plant and equipment | 13,600 | ||||
Intangible assets | 31,400 | ||||
Accrued liabilities | (2,760) | ||||
Accounts payable | (1,487) | ||||
Deferred income taxes | (12,243) | ||||
Net tangible and intangible assets | 80,327 | ||||
Goodwill | 40,271 | ||||
Total purchase price | 120,598 | ||||
Total purchase price | 120,598 | ||||
Less: Cash acquired | (22,887) | ||||
Acquisition of business | 97,711 | ||||
Estimated working capital adjustment due from seller | (878) | ||||
Net cash paid | 98,589 | ||||
Goodwill deductible for tax purposes | 0 | ||||
U.S. Amines, Ltd. | Customer Relationships | |||||
Business Acquisition [Line Items] | |||||
Finite-lived intangibles acquired | $ 30,000 | ||||
Useful life | 20 years | ||||
U.S. Amines, Ltd. | Trademarks | |||||
Business Acquisition [Line Items] | |||||
Finite-lived intangibles acquired | $ 1,000 | ||||
Useful life | 5 years | ||||
Commonwealth Industrial Services (CIS) | |||||
Business Acquisition [Line Items] | |||||
Acquisition of business | $ 9,523 | ||||
Purchase Price | |||||
Cash | 0 | ||||
Accounts receivable | 858 | ||||
Inventories | 712 | ||||
Other current assets | 0 | ||||
Property, plant and equipment | 1,875 | ||||
Intangible assets | 3,920 | ||||
Accrued liabilities | 0 | ||||
Accounts payable | (429) | ||||
Deferred income taxes | 0 | ||||
Net tangible and intangible assets | 6,936 | ||||
Goodwill | 2,587 | ||||
Total purchase price | 9,523 | ||||
Total purchase price | 9,523 | ||||
Less: Cash acquired | 0 | ||||
Acquisition of business | 9,523 | ||||
Estimated working capital adjustment due from seller | 0 | ||||
Net cash paid | 9,523 | ||||
Goodwill deductible for tax purposes | $ 2,587 |
Acquisitions - Asset Acquisitio
Acquisitions - Asset Acquisition (Details) - Commonwealth Industrial Services, Inc. $ in Millions | 1 Months Ended |
Jan. 31, 2021USD ($) | |
Asset Acquisition [Line Items] | |
Net cash paid | $ 9.5 |
Useful life | 15 years |
Subsequent Events (Details)
Subsequent Events (Details) - $ / shares | May 06, 2022 | Mar. 31, 2022 | Mar. 31, 2021 |
Subsequent Event [Line Items] | |||
Cash dividends declared per share (in dollars per share) | $ 0.125 | $ 0 | |
Subsequent Event | |||
Subsequent Event [Line Items] | |||
Cash dividends declared per share (in dollars per share) | $ 0.125 |